This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thom J. Zimmerman, MD, PhD

Arch Ophthalmol. 1997;115(7):914.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

WHEN I FIRST READ the article by Stewart et al¹ in this issue of the ARCHIVES, concerning the daily cost of β-adrenergic blocker therapy, I wanted to shrug it off and simply ignore the information in the article. This reaction was because I believe things are already extremely complicated for the majority who treat glaucoma. But, if you are a glaucoma specialist and all you do is take care of patients with glaucoma, then maybe it's not so complicated. However, most of us who take care of patients with glaucoma are comprehensive ophthalmologists and we need to know much more than just the glaucoma medications. For the majority of clinicians, this whole area of multiple β-blockers, the new glaucoma drugs, the availability of laser, and other treatment modalities can be confusing. I have worked during the last year in a direction toward simplification of information on glaucoma drugs so . . . [Full Text PDF of this Article]

Author Affiliations
Louisville, Ky

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?